AstraZeneca vaccine trial starts at Japan : Still stalled in US

▴ AstraZeneca vaccine trial starts at Japan : Still stalled in US
AstraZeneca vaccine is crossing the hardles one at a time !

A vaccine trial for a front-runner Covid-19 shot from AstraZeneca Plc and the University of Oxford restarted in Japan after studies were halted globally last month when a U.K. participant became ill.

The phase I-II trials resumed after the Japanese regulator gave the go-ahead, according to a statement from AstraZeneca Friday. Studies in the U.K., Brazil, South Africa and India have also restarted in recent weeks.

The news follows the European regulator’s decision this week to begin an accelerated review of the potential shot, a move that could pave the way for the vaccine to become the first in the region to win approval. The “rolling review” allows regulators to see clinical data in real-time so that a vaccine or drug can be brought to the market more quickly if successful.

The British pharmaceutical company and university are still waiting for trials to resume in the U.S.Vaccine trials are currently halted in the US after a study participant in the United Kingdom was reported to have sustained a severe adverse event, thought at the time to be transverse myelitis. Trials have recommenced in the United Kingtom, as well as in South Africa, India and Brazil.

The day before EMA’s announcement of the commencement of the vaccine candidate’s rolling review, Reuters reported that the US Food and Drug Administration (FDA) was expanding an investigation into the AstraZeneca/Oxford candidate to look at earlier vaccine trials that investigated the ChAdOx1 vector for other disease indications.

Back at home, speaking at India Today Healthgiri Awards 2020, Guleria said it is really difficult to say when the vaccine will be available in the country. Also Read - Sputnik V: Trials For Russian Coronavirus Vaccine May Begin in India in Upcoming Weeks

He said from the ongoing trials to the effectiveness of the vaccine — developing a vaccine depends on a lot of factors. Also Read - DCGI Issues Notice to Serum Institute Over Suspension of COVID Vaccine Trial by AstraZeneca Abroad

Talking about the challenges of developing the vaccine, the AIIMS chief said that the big challenge after the vaccine is developed will be its production and distribution on such a large scale.

Responding to a question on Covid-19 peak, Guleria said cases have stabilised marginally over the past few days. He further added that if the current trend continues for the next two weeks, it could clear that India is past its peak.

The development comes at a time when India’s COVID-19 caseload inched closer to 64 lakh-mark with 81,484 infections reported in a day, while the number of people who recuperated from the disease crossed 53 lakh pushing the recovery rate to 83.70 per cent, the Union health ministry said on Friday.

Inputs from - www.Bloomberg.com 

Tags : #AstraZeneca #OxfordUniversityVaccine #JapanTrialStartedAstraZeneca #CovidVaccineNewsNov3 #EuropeanUnion #FDA

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024
Surmandal's Tribute to the Legends of Hindustani Classical MusicMarch 26, 2024
In Moscow, over 350,000 mammograms have been analyzed using artificial intelligence as part of the compulsory health insurance programMarch 26, 2024
Embark on a Creative Journey: "Kala For A Cause" Unveils Pottery Workshop Series March 26, 2024
Healthtech pioneer Aurora Innovation appoints new CEO – expands in Europe with service that streamlines patient-healthcare interactionMarch 26, 2024
In A Rare Feat, 45 YO Woman Walks Within 6 Hrs. Of Dual Robotic Surgery In A Single Operation At HCGMCCMarch 26, 2024
Improve Cancer Care through Automated CT Analysis: Oncoshield – CTMarch 26, 2024